Abeona Therapeutics Inc
ABEO
NASDAQ
Biotechnology
$5.99
USD
-0.36 (-5.67%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $363.91M
Volume 5.4M
Revenue
$14.54M
TTM
— YoY
Gross Margin
71%
TTM
— YoY
Net Income
$66.14M
TTM
+249.7%
YoY
Operating Cash Flow
$-77.73M
TTM
-29.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.4 | 0.0 | 5.4 | 8.7 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.5 | 1.0 | 2.7 |
Gross Profit | 0.0 | 0.4 | -0.5 | 4.4 | 6.0 |
Selling, General & Administrative | 9.8 | 17.1 | 19.3 | 18.8 | 19.5 |
Other Operating Expenses | 0.0 | 0.1 | 0.0 | 1.8 | 0.0 |
Total Operating Expenses | 19.7 | 23.2 | 23.5 | 27.3 | 29.1 |
Operating Income | -19.7 | -22.8 | -24.0 | -22.9 | -23.0 |
EBITDA | -19.2 | -22.2 | -23.4 | -22.0 | -22.3 |
Other Income / Expense | 7.4 | 147.1 | 2.9 | 1.6 | 5.4 |
Total Other Income / Expense | 7.7 | 147.1 | 3.7 | 2.2 | 6.0 |
Income Before Income Taxes | -12.0 | 124.3 | -20.4 | -20.7 | -17.1 |
Income Taxes | 0.0 | 15.5 | -15.2 | -0.2 | 0.0 |
Net Income | -12.0 | 108.8 | -5.2 | -20.5 | -17.1 |
Consolidated Net Income / Loss | -12.0 | 108.8 | -5.2 | -20.5 | -17.1 |
Net Income Attributable to Common Shareholders | -12.0 | 108.8 | -5.2 | -20.5 | -17.1 |
Basic EPS | -$0.24 | $2.07 | -$0.10 | -$0.37 | -$0.30 |
Diluted EPS | -$0.24 | $1.71 | -$0.10 | -$0.22 | -$0.30 |
Basic Shares Outstanding | 49.8M | 52.5M | 54.2M | 55.3M | 56.6M |
Diluted Shares Outstanding | 49.8M | 66.6M | 54.2M | 93.9M | 56.6M |